These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9046118)

  • 21. [Hyperphosphatemia and cardiovascular risk in patients on dialysis].
    Basić-Jukić N; Kes P
    Acta Med Croatica; 2004; 58(3):207-13. PubMed ID: 15503684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated homocysteine levels in patients with end-stage renal disease.
    Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
    Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular problems on hemodialysis: current deficits and potential improvement.
    Ritz E; Bommer J
    Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S71-8. PubMed ID: 19996009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of cardiovascular risk factors in chronic renal disease.
    Coresh J; Longenecker JC; Miller ER; Young HJ; Klag MJ
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S24-30. PubMed ID: 11443765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Yamada S; Kasuga H; Ichimiya S; Kanashiro M; Mitsuhashi H; Maruyama S; Matsuo S; Naruse K; Matsubara T; Murohara T
    Clin Ther; 2007 Jan; 29(1):110-22. PubMed ID: 17379051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardioprotection: an essential component for predialysis chronic renal failure treatment].
    Jungers P; Qualim Z; Nguyen-Khoa T; Massy Z; London G
    Nephrologie; 2003; 24(2):79-88. PubMed ID: 12723513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease.
    Varma R; Garrick R; McClung J; Frishman WH
    Cardiol Rev; 2005; 13(2):98-107. PubMed ID: 15705261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients?
    Fleischmann EH; Bower JD; Salahudeen AK
    Clin Nephrol; 2001 Sep; 56(3):221-30. PubMed ID: 11597037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
    Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
    J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.
    Yao Q; Pecoits-Filho R; Lindholm B; Stenvinkel P
    Scand J Urol Nephrol; 2004; 38(5):405-16. PubMed ID: 15764253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hypertension in hemodialysis patients in Andalucia].
    García Cortés MJ; Ceballos M;
    Nefrologia; 2004; 24(2):149-57. PubMed ID: 15219090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Options in dialysis therapy: significance of cardiovascular findings.
    Wizemann V; Timio M; Alpert MA; Kramer W
    Kidney Int Suppl; 1993 Feb; 40():S85-91. PubMed ID: 8445844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular calcification in nondialyzed patients with chronic kidney disease.
    Qunibi WY
    Semin Dial; 2007; 20(2):134-8. PubMed ID: 17374087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders.
    Bajo MA; del Peso G; Jiménez V; Aguilera A; Villar A; Jiménez C; Selgas R
    Adv Perit Dial; 2000; 16():170-3. PubMed ID: 11045286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
    Sahin S; Sahin GM; Ergin H; Kantarci G
    Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.
    Johnson DW; Craven AM; Isbel NM
    Hemodial Int; 2007 Jan; 11(1):1-14. PubMed ID: 17257349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing cardiovascular disease in the dialysis patient.
    Baig SZ; Coats WC; Aggarwal KB; Alpert MA
    Adv Perit Dial; 2009; 25():147-54. PubMed ID: 19886337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.